Arbor Taps Gene Therapy Veteran to Accelerate Next-Gen Editing Pipeline

CAMBRIDGE, Mass. – May 18, 2026 – Arbor Biotechnologies has appointed Mathew Pletcher, Ph.D., a veteran drug developer with a track record of steering rare disease therapies through to regulatory approval, as its new Chief Scientific Officer. The move signals a strategic acceleration for the clinical-stage gene editing company as it aims to translate the promise of its novel technology into a pipeline of approved medicines.

Dr. Pletcher takes the scientific helm from John Murphy, Ph.D., who is retiring after a five-year tenure that saw Arbor advance its first therapeutic candidate into human clinical trials. In this pivotal transition, Arbor is shifting from a foundational research phase to a new era focused on clinical execution and navigating the complex path to market.

"As we celebrate John's retirement and the foundation he helped build, including Arbor’s first IND, we are excited to welcome Mat, who brings a rare combination of scientific depth, operational expertise, and genuine passion for patients with rare and serious genetic diseases,” said Devyn Smith, Ph.D., Chief Executive Officer of Arbor Biotechnologies in a statement. Dr. Smith emphasized Pletcher's experience as critical for the company's next phase, stating he is "the right scientific leader to help us accelerate our pipeline and realize the full potential of Arbor’s gene editing platform.”

An Architect of Rare Disease Cures

Dr. Pletcher joins Arbor with nearly two decades of experience not just in the lab, but in the trenches of drug development where science meets manufacturing, regulation, and patient access. His career is a roadmap of bringing complex genetic medicines from concept to reality.

Prior to joining Arbor, he served as CSO at Weaver Biosciences and Kisbee Therapeutics. More notably, at Astellas Gene Therapies, he was the SVP and Division Head for Gene Therapy Research and Technical Operations. In this dual role, he was responsible not only for the preclinical pipeline but also for the critical manufacturing and supply chain functions—a crucial skill set for a company like Arbor looking to scale its clinical programs. He was instrumental in the launch of Astellas' large-scale gene therapy manufacturing facility, a testament to his expertise in building the infrastructure required for commercial success.

His tenure as Head of Rare Disease at Roche is particularly significant. There, he played a key role in supporting the approval of Risdiplam (Evrysdi), an oral medicine for spinal muscular atrophy (SMA). Guiding a novel therapy for a devastating rare disease through the regulatory maze demonstrates a capability that goes beyond discovery and is highly coveted by clinical-stage biotechs. His earlier career includes leadership roles at Pfizer's Rare Disease Research Unit and a personal, driving passion for the field; Dr. Pletcher founded and leads a non-profit, Fund for Sight, to support research for Leber Congenital Amaurosis, a genetic condition that affects his daughter.

Beyond CRISPR: Arbor's Technological Edge

At the heart of Arbor's strategy is its proprietary gene editing platform. Originating from the pioneering work of Feng Zhang at the Broad Institute, the company has built what it describes as a "massive discovery engine" to unearth a diverse and differentiated suite of gene editors.

Unlike first-generation CRISPR-Cas9 systems, which have well-documented limitations in size and targeting scope, Arbor’s approach is to find and engineer novel enzymes with more desirable properties. The goal is to develop editors that are smaller, making them easier to package into delivery vehicles like adeno-associated viruses (AAVs) for in vivo therapies. Furthermore, the company seeks editors with greater specificity to minimize the risk of off-target effects—a critical safety concern for all gene-editing therapies. This diverse toolkit could also unlock access to parts of the genome that are inaccessible to standard Cas9, potentially expanding the universe of "druggable" genetic diseases.

This technological promise is being put to the test in Arbor's pipeline. The company's lead program, ABO-101, is currently in a Phase 1b clinical trial for primary hyperoxaluria type 1 (PH1), a rare and life-threatening metabolic disorder that causes severe kidney damage. Arbor is also developing a pipeline for central nervous system disorders, with an initial focus on targets for Amyotrophic Lateral Sclerosis (ALS), a progressive and fatal neurodegenerative disease.

“Arbor has built a differentiated suite of gene editors with the versatility and precision to address diseases that have long been out of reach,” Dr. Pletcher stated. “I’ve spent my career working to bring transformative therapies to patients with serious genetic diseases, and Arbor’s platform and pipeline represent a remarkable opportunity to do exactly that.”

Navigating a Competitive Gene Editing Landscape

Dr. Pletcher’s appointment comes at a critical moment not just for Arbor, but for the entire gene editing field. The landscape is both intensely competitive and rapidly maturing. The first-ever FDA approval of a CRISPR-based therapy, Casgevy from CRISPR Therapeutics and Vertex, has validated the entire approach and set a new bar for innovation.

Arbor finds itself among a cohort of next-generation players, including Beam Therapeutics with its base editing technology and Prime Medicine with its "search-and-replace" prime editors, all vying to prove their platforms offer superior precision, safety, or versatility.

In the specific indication for its lead program, PH1, Arbor faces established competition from a different technological class. Alnylam Pharmaceuticals’ Lumasiran, an RNA interference (RNAi) therapeutic, is already approved and effectively reduces the toxic oxalate production that defines the disease. For ABO-101 to succeed, it will need to demonstrate a compelling clinical profile, potentially offering a one-time, permanent cure that represents a significant advantage over chronic RNAi therapy.

This is precisely the environment where a leader like Dr. Pletcher is most valuable. His experience in both gene therapy operations and late-stage clinical development will be essential in designing and executing trials that can differentiate Arbor’s candidates. His appointment is a clear statement of intent: Arbor is ready to move beyond the promise of its platform and fight for a place in the new era of genomic medicine, translating its unique scientific tools into tangible therapies for patients in desperate need.